Business
CSL buys in to ‘long term’ haemophilia treatment in $655m deal – Sydney Morning Herald
The biotechnology giant has a plan to commercialise a treatment which could reduce treatments for haemophilia patients.
“Our vision with haemophilia B patients is to offer transformational treatment paradigms which help free them from the lifelong burden of this disease,” he said.
AMT-061 is an in-vivo gene therapy, …
Continue Reading